Background and Purpose-Local infections of the head or neck are a cause of cerebral venous thrombosis. Treatment of infectious cerebral venous thrombosis with heparin is controversial. We examined whether this treatment was associated with intracranial hemorrhagic complications and poor clinical outcome. Methods-We retrieved data from a prospective cohort study of 624 cerebral venous thrombosis patients. We compared patients with and without an infection of the head or neck and anticoagulated versus not anticoagulated. We examined death or dependency and new intracerebral hemorrhages. Results-Six hundred four of 624 patients were eligible for the study. Fifty-seven patients had an infection of the head or neck (9.4%). Comparing data between infection and noninfection patients, the frequency of therapeutic doses of heparin was similar in both groups (82.5% versus 83.7%). New intracerebral hemorrhages were more common in patients with an infection (12.3% versus 5.3%; P=0.04), but death or dependency did not differ between patients with and without an infection (15.8% versus 13.7%). In patients with an infection of the head or neck, there was no significant difference in the frequency of new intracerebral hemorrhages and poor outcome between patients who did or did not receive therapeutic doses of heparin. Conclusions-New intracerebral hemorrhages were more frequent in patients with an infection. The use of therapeutic doses of heparin did not seem to influence the risk of new intracranial hemorrhages or poor clinical outcome, but the number of patients who did not receive anticoagulation was too small to draw firm conclusions about safety of heparin in adults with cerebral venous thrombosis and an infection of the head or neck.
L ocal infections of the head or neck can cause cerebral venous thrombosis (CVT). 1, 2 Common examples include ear infections that propagate to the lateral sinuses, cutaneous facial infections that spread to the cavernous sinus, and intracranial infections, such as meningitis and empyema. In older studies, ≈20% to 60% of patients with CVT had an associated infection of the head or neck, [3] [4] [5] [6] [7] but recent publications show that this proportion has decreased to ≈6% to 12% in the developed world, 1, 8 probably because of improved antibiotic treatment.
On the basis of limited data from randomized trials, heparin has been the primary therapy for patients with CVT. [9] [10] [11] [12] [13] [14] Patients with an infection of the head or neck, however, were not included in these trials, and it is unknown whether this recommendation should apply to these patients. Limited data suggest that anticoagulant therapy in patients with meningitis is associated with a higher rate of intracerebral hemorrhagic complications 15 and increased mortality. 16 With the exception of case reports, 17, 18 there are no data on the use of heparin in patients with CVT and a concurrent infection. International guidelines for CVT also do not provide a separate recommendation on the use of heparin in this subgroup. 13, 14 The International Study on Cerebral Venous and Dural Sinus Thrombosis (ISCVT) is the largest prospective cohort study on adult CVT. 19 In the current study, we have analyzed patients from this cohort who had a concurrent infection of the head or neck. Specific aims were to determine how often these patients were treated with therapeutic doses of heparin and whether the use of heparin was associated with intracranial hemorrhagic complications and poor clinical outcome.
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Methods

Study Design and Patient Selection
The organization of the ISCVT has been described previously. Briefly, ISCVT was a prospective international observational cohort study that included 624 consecutive adult patients with symptomatic CVT between 1998 and 2001. 19 Extensive information on baseline clinical characteristics, radiological findings, treatment, and complications during admission were recorded on a standardized case record form. A list of potential risk factors was attached to the case record form, including different types of infections: regional infections (meningitis or other central nervous system [CNS] infections, infections of parameningeal neighboring structures [cranial skin and ear, nose, and throat [ENT]), and generalized or distant infections (HIV infection or other systemic infections). For the current study, we identified all patients with an infection of the head or neck, defined by the presence of an ENT, faciocranial skin, or CNS infection. The diagnosis of ENT infection and their types was established by local investigators. CNS infection was confirmed by the culture of cerebrospinal fluid or explorative surgery. We excluded patients with infections at other locations because a causal relationship between distant infections and CVT is unclear.
Neuroimaging
CVT was confirmed by magnetic resonance venography, computed tomographic venography, conventional angiography, surgery, or autopsy. At baseline, all patients received computed tomography or magnetic resonance imaging. Repeated cerebral imaging was performed at the discretion of the treating physician, and documentation of new parenchymal lesions (symptomatic or not) was required. We classified intracerebral lesions as nonhemorrhagic lesion (focal edema or venous infarct without signs of hemorrhage) and intracerebral hemorrhage (ICH; hemorrhagic infarct or ICH). There was no central reading committee of computed tomography or magnetic resonance imaging or validation of the reports of the local investigators. The decision to treat the patient with heparin was left to the local investigator. The dose (prophylactic or therapeutic) 20 and the type of heparin were registered, and monitoring of anticoagulant therapy was performed according to local hospital protocol. Complications, such as seizures and their types, were established by local neurologists.
End Points
We considered death or dependency (defined as a modified Rankin Scale score, > 2) at last follow-up as the primary outcome. Secondary end points were all-cause mortality at 30 days (the different causes of death were recorded on a case record form), 21 complete recovery (modified Rankin Scale score, 0 or 1) at last follow-up, neurological worsening, and the occurrence of a new ICH after diagnosis. Systemic hemorrhages were not recorded, but blood transfusions or any surgery were registered.
Statistical Analysis
We first compared patients with an infection of the head or neck with those without an infection. We then compared patients with an infection of the head or neck treated with heparin treatment in therapeutic dosages to those who did not receive heparin or who received heparin only in prophylactic dose.
For comparison of continuous data, we used a Student t test or a Mann-Whitney U test and for categorical data a χ 2 or Fisher exact test, whichever was appropriate. We provide continuous data as a mean with SD or, if the data did not have a normal distribution, as a median with interquartile range. Categorical variables are given as the number of patients in which the variable was present and the total number of patients for which that variable was reported. P values of <0.05 were considered statistically significant. All data were analyzed with SPSS version 21 (IBM Inc, Armonk, NY).
Results
Of the 624 patients in the ISCVT, 77 patients had an infection (12.3%). Twenty of these had an infection outside the head or neck region (respiratory tract [n=4], urinary tract [n=3], gastroenteritis [n=3], hepatitis [n=2], HIV infection [n=2]
, and other [n=6]), and these patients were excluded. Therefore, our study cohort consisted of 57 patients with a head or neck infection and 547 patients without an infection ( Figure) .
Type of Infection
Of the 57 patients with CVT and an infection of the head or neck, 51 patients (89.5%) had an ENT infection. The exact type of ENT infection was specified in 29 patients: otitis/mastoiditis (n=18), sinusitis (n=9), pharyngitis (n=1), and tonsillitis (n=1). Thirteen of 57 patients (22.8%) had a CNS infection, confirmed by cerebrospinal fluid culture (n=12) or surgery (n=1). Seven patients had both an ENT and CNS infection (12.3%). Seven patients had a distant infection in addition to the regional infection: HIV infection (3), gastroenteritis (2), sepsis (1), and endocarditis (1).
Baseline Characteristics
Baseline characteristics of the 57 patients with a head or neck infection are shown in Table 1 . Patients with a head or neck infection less often were women (59.6% versus 77.0%; P=0.004) and more often had papilledema (47.3% versus 26.9%; P=0.001) and diplopia (26.3% versus 12.2%; P=0.003) compared with patients without an infection. About 57.9% of patients with an infection had an additional risk factor. Thrombosis of the cavernous sinus occurred more frequently in patients with an infection (7.0% versus 0.7%; P<0.001). An ICH at baseline was less common in patients with an infection (21.1% versus 41.6%; P=0.003). All patients with an infection and ICH at baseline had an ENT infection, and none had a CNS infection. Seven of 13 patients with a CNS infection (53.8%) had a nonhemorrhagic lesion at baseline compared with 6 of 44 patients with an ENT infection (13.6%). The proportion of patients who received heparin in therapeutic doses did not differ between patients with and without an infection (82.5% versus 83.7%).
Complications During Admission
A quarter of the patients in each group deteriorated neurologically during admission (Table 2) . A new ICH occurred more often in patients with an infection of the head or neck compared with those without an infection (7/57, 12.3% versus 29/545, 5.3%; P=0.04). When specified by the type of infection, 3 of 13 patients (23.1%) with a CNS infection developed a new ICH compared with 4 of 44 patients (9.1%) with an ENT infection. There was no statistically significant difference in the frequency of new nonhemorrhagic lesions between patients with an infection of the head or neck and those without an infection.
Clinical Outcome
Nine patients (15.8%) with an infection of the head or neck were dead or dependent (modified Rankin Scale score, >2) at last follow-up compared with 75 patients (13.7%) without an infection (Table 2 ). Death or dependency was especially high in patients with a CNS infection (4/13; 30.8%). Mortality did not differ significantly between the groups (5.3% versus 3.3%; P=0.44). In total, 21 patients died. In 16 of 18 patients without an infection who had died, death was caused by cerebral herniation and therefore directly related to CVT. In the other 2 patients, the cause of dead was not reported. In patients with an infection of the head or neck, death caused by cerebral herniation occurred in 1 of 3 patients. In the 2 other patients, death was not directly related to CVT (1 caused by HIV infection and caused by endocarditis). The full distribution of the modified Rankin Scale at last follow-up in each group is shown in Figure I in the online-only Data Supplement. The median time to last follow-up was 476 days (interquartile range, 332-760 days).
Heparin in Patients With an Infection of the Head or Neck
Forty-seven of 57 patients (82.5%) with an infection received therapeutic doses of heparin in the acute phase. Of the remaining 10 patients, 4 received prophylactic doses of heparin and 6 received no heparin. There were no major differences in demographics, clinical manifestations, or baseline radiological findings between patients who did or did not receive therapeutic dose of heparin ( Table I in the online-only Data Supplement). Clinical deterioration occurred more often in patients treated with heparin (31.9% versus 10.0%; P=0.17; Table 3 ), but there was no difference in the frequency of new parenchymal lesions. All patients with a new ICH were treated with therapeutic dose of heparin, with the exception of 2 patients without an infection of the head or neck and 1 patient with a CNS infection and endocarditis. Clinical outcome at follow-up did not differ between patients who did or did not receive therapeutic dose of heparin.
Discussion
Our data indicate that a local infection, nowadays, is an uncommon cause of CVT in adults. The frequency of an infection as a risk factor is similar to what was reported in another recent cohort study. 22 Even in developing countries, the reported fraction of a local infection in adults with CVT is only 15%. 23 One outlier is large retrospective study from the United States based on administrative data, which found that >80% of CVT cases were pyogenic. 24 The over-representation of pyogenic CVT in this study could be due to an underreporting of nonpyogenic CVT or more likely to an erroneous code for CVT: the diagnosis of CVT was drawn from a national database. 24 Patients with an infection of the head or neck more often had papilledema and diplopia at presentation and less often an ICH. This would suggest that these patients more often had intracranial hypertension because of occlusion of a large sinus and less often occlusion of a cortical vein. Even if we omit the cases with cavernous sinus thrombosis, which are usually septic, the differences in papilledema and ICH were still significant.
An important observation is that a new ICH occurred more often in patients with an infection of the head or neck (12.3% versus 5.3%) despite the fact that a baseline ICH was less common in these patients. The increased risk of new ICH in patients with an infection of the head or neck is especially related to the increased risk of new ICH in patients with a CNS infection. Three of 13 patients (23.1%) with a CNS infection developed a new ICH. One of them was not treated with the therapeutic dose of heparin and had additionally an endocarditis. In patients with an ENT infection, 4 of 44 patients (9.1%) developed a new ICH during hospitalization, which is closer to the incidence of new ICH in patients without an infection (5.3%). Remarkably, we found that patients with a CNS infection had a higher rate of nonhemorrhagic infarcts at baseline imaging compared with patients with an ENT infection (53.8% versus 13.6%, respectively). The underlying pathophysiology of the higher frequency of new ICH, especially in patients with a CNS infection, is unknown but could be related because of the extension of the thrombus to the cortical veins. A pathophysiological mechanism may be that there is a dysregulation of both the coagulation and fibrinolytic pathways. The massive clotting may result in the local depletion of coagulation factors, which together with microvascular damage, vasculitis, and cerebral infarction might lead to the increased risk of ICH. 25 The proportion of patients with CVT and an infection treated with the therapeutic dose of heparin (82.5%) is similar to that of the entire ISCVT cohort (83.3%). 26 Apparently, most neurologists believe that heparin is indicated and safe in these patients although there is no evidence from randomized trials for the use of heparin in patients with a septic CVT. The use of therapeutic dose of heparin did not seem to influence the risk of new ICH in our study, but the number of patients who did not receive anticoagulation was too small to draw firm conclusions. Interestingly, clinical deterioration occurred 3× more often in patients treated with therapeutic dose of heparin (31.9% versus 10.0%), but these data should be interpreted with caution because of the small numbers and the fact that this analysis was not adjusted for potential confounders. The causes for the clinical deterioration of the patients with an infection of the head or neck who received therapeutic dose of heparin are not completely understood and may need clarification in further studies. Uncertainty about the use of therapeutic dose of heparin remains especially for the group of patients with a CNS infection because of the small number of patients and because there are data that suggest that these patients have a higher risk of hemorrhage if treated with anticoagulation. 27 The results of our study cannot be extrapolated to pediatric patients with CVT because the ISCVT included only adult patients. A previous study indicates that treatment with therapeutic doses of heparin was not associated with serious hemorrhages in selected pediatric patients with CVT. 28 Our study has several limitations. First, we could only include a limited number of patients with an infection of the head or neck and only 13 patients with an underlying CNS infection. Second, infections of the head or neck were categorized as diagnosed by the clinician and not judged by an adjudication committee according to predefined diagnostic criteria. Another limitation is the lack of central reading of the imaging results and the fact that repeat imaging was not performed in all patients. In addition, no difference could be made between symptomatic and asymptomatic new parenchymal lesions. Because this is an observational study and the ISCVT was not designed to this specific analysis, our data cannot be used for strong treatment recommendations. Although both groups were comparable on most baseline characteristics, we cannot exclude the risk of bias. Adjusting for prognostic factors was impossible because the group of patients with an infection of the head or neck was too small.
In conclusion, the ISCVT data show that treatment with therapeutic doses of heparin is frequently given to adults with CVT and an infection of the head or neck. Although IQR indicates interquartile range; and mRS, modified Rankin Scale. *Defined as Glasgow Coma Scale on admission <15 (stupor, 14-9; coma, <9). †Includes executive deficits (frontal lobe syndromes), delirium and personality, or other acute behavioral changes but not disturbances of the instrumental cognitive domains, such as aphasia, apraxia, agnosia, amnesia, or visuospatial disturbances.
‡Patients who did not receive repeated imaging were scored as no new parenchymal lesions.
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the potential benefit of therapeutic doses of heparin in adults with CVT and an infection of the head or neck cannot be determined with confidence from the ISCVT data, the results of our study suggest that the use of heparin did not seem to influence this risk of new ICHs or of bad outcome, but the number of patients who did not receive anticoagulation was too small to draw firm conclusions about safety of heparin in adults with CVT and an infection of the head or neck.
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